Bruce Eaton, Ph.D.

Bruce Eaton, Ph.D.

Bruce Eaton, Ph.D.

President & CEO
i2 Pharmaceuticals & Velocity Sciences

Bruce Eaton represents two organizations. Velocity Sciences Inc. as President and CEO; and i2 Pharmaceuticals Inc., as Chairman and CEO.

Velocity Sciences is a life sciences company that provides contract services in assay development as its primary source of revenue. The company was founded in 2014 through strategic partnership with companies in the life sciences. The company is actively establishing partnerships to develop research applications using its proprietary technology in multiplexed arrays. The company continues to expand its service business while building new sensitive and specific assays in the immuno-oncology (IO) space. Overall the company provides content and assay solutions for the life sciences market from basic to translation clinical research.

i2 pharmaceuticals provides hit discovery and lead optimization technology to its strategic partners in the pharmaceutical industry. Our core technology allows for drug discovery enabling "big data" in medicinal chemistry to be used with "big data" in genomics and phenotypic screens. Using a variety of technologies, i2 creates tools for pharmaceutical drug discovery and development; in addition to proprietary medicinal chemistry services for the expansion of intellectual property protection of early and late stage pharmaceutical assets. As we acquire additional technology assets the company is poised to play a role in oncology therapeutics. Our goal is to establish strategic partnerships to develop personalized therapeutics in the IO space. Our core technology allows for drug discovery enabling "big data" in medicinal chemistry to be used with "big data" in genomics and phenotypic screens.